Clinical trial • Phase I • Oncology
Clinical trial in Metastatic Solid Tumor | Advanced Solid Tumor | Non-small cell lung cancer | SMARCA4-deficient tumor
Phase I trial for Metastatic Solid Tumor | Advanced Solid Tumor | Non-small cell lung cancer | SMARCA4-deficient tumor. 228 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Metastatic Solid Tumor | Advanced Solid Tumor | Non-small cell lung cancer | SMARCA4-deficient tumor
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 27-05-2025
- First CTIS Authorization Date
- 15-09-2025
Trial design
Phase I trial across 8 sites in Spain, France, Germany.
- Target Sample Size
- 228
Recruitment
- Planned Sample Size
- 228
- Recruitment Window Months
- 38
Geography
- Total Number Of Sites
- 8
- Total Number Of Participants
- 112
Spain
- Earliest CTIS Part Ii Submission Date
- 09-09-2025
- Latest Decision Or Authorization Date
- 22-09-2025
- Processing Time Days
- 13
- Number Of Sites
- 2
- Number Of Participants
- 37
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Medical Oncology
- Contact Person Name
- Elena Garralda Cabanas
- Contact Person Email
- egarralda@vhio.net
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Oncology
- Contact Person Name
- Victor Moreno
- Contact Person Email
- Victor.moreno@startmadrid.com
France
- Earliest CTIS Part Ii Submission Date
- 11-06-2025
- Latest Decision Or Authorization Date
- 03-11-2025
- Processing Time Days
- 145
- Number Of Sites
- 3
- Number Of Participants
- 48
Sites
- Site Name
- Institut Gustave Roussy
- Department Name
- Department of Medicine / DITEP
- Contact Person Name
- Rastislav BAHLEDA
- Contact Person Email
- rastilav.bahleda@gustaveroussy.fr
- Site Name
- Institut Curie
- Department Name
- Pneumology
- Contact Person Name
- Nicolas GIRARD
- Contact Person Email
- nicolas.girard2@curie.fr
- Site Name
- Institut Bergonie
- Department Name
- Medical Oncology
- Contact Person Name
- Antoine ITALIANO
- Contact Person Email
- a.italiano@bordeaux.unicancer.fr
Germany
- Earliest CTIS Part Ii Submission Date
- 12-09-2025
- Latest Decision Or Authorization Date
- 29-10-2025
- Processing Time Days
- 47
- Number Of Sites
- 3
- Number Of Participants
- 27
Sites
- Site Name
- Krankenhaus Nordwest GmbH
- Department Name
- Klinik für Onkologie und Hämatologie
- Contact Person Name
- Akin Atmaka
- Contact Person Email
- atmaca.akin@khnw.de
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Department Name
- Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie
- Contact Person Name
- Damian Rieke
- Contact Person Email
- damian.rieke@charite.de
- Site Name
- Universitaetsklinikum Essen AöR
- Department Name
- Department of Medical Oncology
- Contact Person Name
- Martin Schuler
- Contact Person Email
- martin.schuler@uk-essen.de
Sponsor
Primary sponsor
- Full Name
- Eli Lilly & Co.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)